You can buy or sell Orphazyme and other stocks, options, and ETFs commission-free!
Orphazyme A/S engages in development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Mørkeberg Hinsby, Marja Jäättela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark. The listed name for ORPH is Orphazyme A/S American Depositary Shares.
Anders Fink Vadsholt
Copenhagen, Capital Region
52 Week High
52 Week Low